Valuation : Vyome Holdings, Inc.

Market Cap 14.46M 12.46M 11.8M 10.69M 20.06M 1.38B 20.16M 140M 53.87M 703M 54.3M 53.11M 2.22B P/E 2026 *
-3.61x
P/E 2027 * -2.58x
Enterprise Value 14.46M 12.46M 11.8M 10.69M 20.06M 1.38B 20.16M 140M 53.87M 703M 54.3M 53.11M 2.22B EV / Sales 2026 *
108x
EV / Sales 2027 * 72.3x
Free-Float
47.12%
Yield 2026 *
-
Yield 2027 * -
1 day-1.90%
1 week-7.21%
Current month-4.64%
1 month-7.21%
3 months-10.43%
6 months-13.08%
Current year-40.12%
1 week 2.05
Extreme 2.05
2.23
1 month 2.05
Extreme 2.05
2.36
Current year 1.75
Extreme 1.75
3.89
1 year 1.75
Extreme 1.75
9.56
3 years 1.75
Extreme 1.75
16
5 years 1.75
Extreme 1.75
16
10 years 1.75
Extreme 1.75
16
Date Insider Type Main position Quantity % Market Cap. Importance
9/1/26 Free

Director

120,000 1.7098%
11/13/25 Free

Founder

615,149 11.1972%
11/13/25 Free

Director

17,833 0.3246%
Change 5-day change 1-year change 3-year change Capi.($)
-1.90%-7.21%-71.78% - 14.46M
-0.71%-6.35%-2.99%+9.59% 45.48B
+0.21%-2.98%+337.74%+519.55% 43.69B
+1.74%-2.24%+39.82%+20.76% 43.09B
+1.38%-3.28%+6.84%+67.62% 39.4B
-1.44%-5.26%+8.78%+36.85% 31.91B
+0.87%-2.60% - - 17.31B
+0.75%-0.64%+19.75%+110.17% 16.4B
-0.31%-2.78%+10.78%+31.02% 14.24B
+1.93%-3.55%+82.00%+41.17% 13.28B
Average +0.25%-3.94%+47.88%+104.59% 26.48B
Weighted average by Cap. +0.41%-3.67%+74.54%+123.90%

Financials

2026 *2027 *
Net sales 133K 115K 109K 98.59K 185K 12.74M 186K 1.29M 497K 6.48M 501K 490K 20.48M 200K 172K 163K 148K 277K 19.11M 279K 1.94M 745K 9.72M 751K 735K 30.72M
Net income -4M -3.45M -3.26M -2.96M -5.55M -382M -5.58M -38.76M -14.9M -194M -15.02M -14.69M -614M -7.85M -6.76M -6.4M -5.8M -10.88M -750M -10.94M -76.02M -29.23M -381M -29.47M -28.82M -1.21B
Net Debt - -
Logo Vyome Holdings, Inc.
Vyome Holdings, Inc. is a clinical-stage healthcare holding company. The Company is focused on leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. Its clinical program VT1953 Gel is focused on cancer patients who are suffering from malignant fungating wounds (MFW). Its preclinical development program, VT1908, is a non-steroidal eye drop, which is focused on Uveitis. Its other business unit is focused on offering artificial intelligence (AI)-driven healthcare solutions across mental health and inflammation care, digital therapeutics and psychoneuroimmunology.
Employees
14
Date Price Change Volume
26-09-11 US$2.060 -1.90% 17,529
26-09-10 US$2.100 +1.94% 3,199
26-09-09 US$2.060 -1.44% 3,988
26-09-08 US$2.090 -5.86% 19,171
26-09-04 US$2.220 -0.45% 2,307
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.060USD
Average target price
8.833USD
Spread / Average Target
+328.80%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. HIND Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!